Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer

Table 2

Ablation characteristics by patient group.

Variable	rhTSH group (n = 18)	THW group (n = 27)	P
Cumulative radioiodine activity before ablation success evaluation, GBq (mCi), mean ± SD	5.62 ± 1.30 (152 ± 35)	5.85 ± 1.22 (158 ± 33)	0.34
Ablation activity, GBq (mCi), mean ± SD	4.70 ± 1.41 (127 ± 38)	4.85 ± 1.11 (131 ± 29)	0.32
Ablation activity category, n
3.70 GBq (100 mCi)	9	11
5.55 GBq (150 mCi)	4	9	0.08
7.40 GBq (200 mCi)	5	7
Patients receiving 1 additional radioiodine therapy before ablation success evaluation, % (n)	28% (5)	26% (7)	0.43
Timing of ablation success evaluation, months after ablation, mean ± SD	10 ± 3	9 ± 5	0.18
Ablation status, % (n)
Success	83% (15)	67% (18)	0.02
Failure	17% (3)	33% (9)

dxWBS: diagnostic whole-body scintigraphy; rhTSH: recombinant human thyroid-stimulating hormone; rxWBS: posttherapy whole-body scintigraphy; SD: standard deviation; Tg: serum thyroglobulin; THW: thyroid hormone withdrawal or withholding; TSH: thyrotropin.